138 related articles for article (PubMed ID: 8699855)
1. Prevention studies with pentoxifylline: new clinical projects.
Eugène-Jolchine I; Milpied N
J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S143-6. PubMed ID: 8699855
[TBL] [Abstract][Full Text] [Related]
2. [Anti-inflammatory effects of pentoxifylline: importance in cardiac surgery].
Groesdonk HV; Heringlake M; Heinze H
Anaesthesist; 2009 Nov; 58(11):1136-43. PubMed ID: 19890615
[TBL] [Abstract][Full Text] [Related]
3. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
[TBL] [Abstract][Full Text] [Related]
4. Controlled therapeutic trials of pentoxifylline in relapsing-experimental auto-immune encephalomyelitis.
Grassin M; Brochet B; Coussemacq M; Brochet H
Acta Neurol Scand; 1998 Jun; 97(6):404-8. PubMed ID: 9669475
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation.
Bianco JA; Appelbaum FR; Nemunaitis J; Almgren J; Andrews F; Kettner P; Shields A; Singer JW
Blood; 1991 Sep; 78(5):1205-11. PubMed ID: 1878587
[TBL] [Abstract][Full Text] [Related]
6. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
MMW Fortschr Med; 2002 May; 144(21):54. PubMed ID: 12134429
[No Abstract] [Full Text] [Related]
7. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A
Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035
[TBL] [Abstract][Full Text] [Related]
8. Does long-term continuous administration of pentoxifylline affect platelet function in the critically ill patient?
Boldt J; Müller M; Heesen M; Heyn S; Hempelmann G
Intensive Care Med; 1996 Jul; 22(7):644-50. PubMed ID: 8844228
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of cilostazol and other therapies for intermittent claudication.
Dawson DL
Am J Cardiol; 2001 Jun; 87(12A):19D-27D. PubMed ID: 11434896
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blinded placebo-controlled clinical trial on protective effects of pentoxifylline on gentamicin nephrotoxicity in infectious patients.
Mousavinasab SR; Akhoundi-Meybodi Z; Mahmoudi L; Karimzadeh I
Clin Exp Nephrol; 2021 Aug; 25(8):844-853. PubMed ID: 33792832
[TBL] [Abstract][Full Text] [Related]
11. [Pentoxifylline: a cheap substitute for anti-TNFalpha agents?].
Koenig M; Cathébras P; Guy C; Rousset H
Rev Med Interne; 2006 May; 27(5):400-5. PubMed ID: 16309798
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for peripheral arterial disease: emerging therapeutic options.
Jaff MR
Angiology; 2002; 53(6):627-33. PubMed ID: 12463615
[TBL] [Abstract][Full Text] [Related]
13. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities].
Maksimović ZV
Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398
[TBL] [Abstract][Full Text] [Related]
14. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial.
Attal M; Huguet F; Rubie H; Charlet JP; Schlaifer D; Huynh A; Laurent G; Pris J
Blood; 1993 Aug; 82(3):732-6. PubMed ID: 8338943
[TBL] [Abstract][Full Text] [Related]
15. Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6.
Lee TM; Su SF; Hwang JJ; Tseng CD; Chen MF; Lee YT; Wang SS
Atherosclerosis; 2001 Oct; 158(2):471-6. PubMed ID: 11583728
[TBL] [Abstract][Full Text] [Related]
16. Immunological mechanisms of pentoxifylline in chronic heart failure.
Shaw SM; Shah MK; Williams SG; Fildes JE
Eur J Heart Fail; 2009 Feb; 11(2):113-8. PubMed ID: 19168508
[TBL] [Abstract][Full Text] [Related]
17. Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Regensteiner JG; Stewart KJ
Nat Clin Pract Cardiovasc Med; 2006 Nov; 3(11):604-10. PubMed ID: 17063165
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis.
Windmeier C; Gressner AM
Gen Pharmacol; 1997 Aug; 29(2):181-96. PubMed ID: 9251897
[TBL] [Abstract][Full Text] [Related]
19. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
[TBL] [Abstract][Full Text] [Related]
20. Pentoxifylline for the treatment of HIV infection and its complications.
Dezube BJ; Lederman MM
J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S139-42. PubMed ID: 8699854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
